Femme Homme
- | Pays :
- Russian Federation
- Romania
- Ukraine
- Les 2 autres...
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.
Critère d'inclusion
- Breast Neoplasms ,Neoplasms, Hormone-Dependent